COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 293: Articles 2921-2930  | Next

Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing
Bhattacharya, S., Jenkins, M. C., Keshavarz-Joud, P., Bourque, A. R., White, K., Barkane, A. M. A., Bryksin, A. V., Hernandez, C., Kopylov, M., Finn, M. G.
10.1101/2024.02.24.581861 — Posted: 2024-02-26
Biochemical characterization of naturally occurring mutations in SARS-CoV-2 RNA-dependent RNA polymerase
Danda, M., Klimesova, A., Kuskova, K., Dostalkova, A., Pagacova, A., Prchal, J., Kapisheva, M., Ruml, T., Rumlova, M.
10.1101/2024.02.24.581855 — Posted: 2024-02-26
Prognostic factors for mortality, ICU, MIS-C and hospital admission due to SARS-CoV-2 in paediatric patients: A systematic review and meta-analysis
Vardavas, C. I., Nikitara, K., Mathioudakis, A., Delialis, D., Marou, V., Ramesh, N., Stamatelopoulos, K., Georgiopoulos, G., Phalkey, R., Leonardi-Bee, J., Deogan, C., Lamb, F., Mougkou, A., Pharris, A., Suk, J. E.
10.1101/2024.02.23.23298451 — Posted: 2024-02-24
Global patterns of rebound to normal RSV dynamics following COVID-19 suppression
Thindwa, D., Li, K., Cooper-Wootton, D., Zheng, Z., Pitzer, V. E., Weinberger, D. M.
10.1101/2024.02.23.24303265 — Posted: 2024-02-24
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
HITES, M., MASSONNAUD, C. R., JAMARD, S., Goehringer, F., DANION, F., REIGNIER, J., DE CASTRO, N., GAROT, D., LARRANAGA LAPIQUE, E., LACOMBE, K., TOLSMA, V., FAURE, E., MALVY, D., STAUB, T., COURJON, J., CAZENAVE-ROBLOT, F., DYRHOL RIISE, A. M., LE TURNIER, P., MARTIN BLONDEL, G., ROGER, C., AKINOSOGLOU, K., LE MOING, V., PIROTH, L., SELLIER, P., LESCURE, X., TROSEID, M., CLEVENBERGH, P., DALGARD, O., GALLIEN, S., GOUSSEFF, M., LOUBET, P., BOUNES - VARDON, F., VISEE, C., BELKHIR, L., BOTELHO-NEVERS, E., CABIE, A., KOTANIDOU, A., LANTERNIER, F., ROUVEIX-NORDON, E., SILVA, S., THIERY, G., POIGNA
10.1101/2024.02.23.24302586 — Posted: 2024-02-24
Changes in opioid prescribing during the COVID-19 pandemic in England: cohort study of 20 million patients in OpenSAFELY-TPP
Schaffer, A. L., Andrews, C. D., Brown, A. D., Croker, R., Hulme, W. J., Nab, L., Quinlan, J., Speed, V., Wood, C., Wiedemann, M., Massey, J., Inglesby, P., Bacon, S. C., Mehrkar, A., Bates, C., Goldacre, B., The OpenSAFELY Collaborative, , Walker, A. J., MacKenna, B.
10.1101/2024.02.23.24303238 — Posted: 2024-02-24
A Population-Based Cross-Sectional Investigation of COVID-19 Hospitalizations and Mortality Among Autistic People
Nijhof, D., Sosenko, F., MacKay, D., Fleming, M., Jani, B. D., Pell, J., Hatton, C., Cairns, D., Henderson, A., Ward, L. M., Rydzewska, E., Gardani, M., Millington, E., Melville, C.
10.1101/2024.02.23.24303274 — Posted: 2024-02-24
Prospective study of machine learning for identification of high-risk COVID-19 patients
Frausto-Avila, C. M., Leon-Montiel, R. d. J., Quiroz-Juarez, M. A., U'Ren, A. B.
10.1101/2024.02.21.24303159 — Posted: 2024-02-23
Thrombotic and thromboembolic events, with or without thrombocytopenia, following viral vector-based COVID-19 vaccines administration: a systematic review protocol.
Ramos-Rojas, J., Pena, J., Pinto-Diaz, C., Veloso, V., Rada, G., Molina-Leon, H. F.
10.1101/2024.02.22.24303207 — Posted: 2024-02-23
Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant
Chemaitelly, H., Coyle, P., Kacem, M. A. B., Ayoub, H., Tang, P., Hasan, M. R., YASSINE, H. M., Althani, A., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M. H., Al-Khal, A., Bertollini, R., Abu-Raddad, L. J.
10.1101/2024.02.22.24303193 — Posted: 2024-02-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).